<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Chatzidionysiou, Katerina</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy of Different Doses of Rituximab for the Treatment of RA: Data from the CERERRA Collaboration</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">The approved dose of rituximab for the treatment of rheumatoid arthritis (RA) is 1000 mg × 2, but some data have suggested similar clinical efficacy with rituximab 500 mg × 2. The objective of this analysis was to compare the efficacy of the 2 doses, given as first or second treatment courses. The data for this analysis were obtained from the European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis [CERERRA], which includes 10 European registries.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>